Oppenheimer Initiates Coverage On Evolent Health with Outperform Rating, Announces Price Target of $45
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones initiates coverage on Evolent Health (EVH) with an Outperform rating and sets a price target of $45.
March 01, 2024 | 12:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer initiated coverage on Evolent Health with an Outperform rating and a price target of $45, indicating a positive outlook.
The initiation of coverage by a reputable analyst with an Outperform rating and a high price target suggests a strong bullish sentiment towards Evolent Health. This is likely to positively influence investor perception and could lead to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100